Daniel Rabinowitz, serving as both SEC and Chief Legal Officer at Natera, Inc. (NASDAQ:NTRA), executed sales of his common stock holdings totaling approximately $4.6 million during January 20 and 21, 2026. The transactions involved selling 19,672 shares at prices ranging from $234.7384 to $235 per share.
According to a Form 4 filed with the U.S. Securities and Exchange Commission, Rabinowitz sold 19,234 shares on January 20 at $234.7384 each. The following day, he disposed of an additional 438 shares, selling at $235 per share.
In addition to divesting shares, Rabinowitz also acquired 856 shares through the exercise of restricted stock units on January 20. These units were exercised at no cost, in line with company compensation policies.
In parallel with these insider transactions, Natera disclosed provisional financial results for the fourth quarter of 2025, highlighting substantial growth metrics. The company anticipates a near 40% year-over-year revenue increase, significantly outperforming analyst expectations. Correspondingly, test volume rose by about 17% during the quarter, reflecting robust operational activity.
Furthermore, Natera announced a collaborative initiative with Exelixis targeting stage 3 clinical trials for colorectal cancer. This partnership centers on using Natera's Signatera molecular residual disease (MRD) assay to identify eligible patients exhibiting residual disease after treatment, which could influence trial enrollment criteria.
Following these developments, Canaccord Genuity reaffirmed its Buy rating on Natera's stock and maintained a price target of $285.00, citing the strong preliminary results as an underpinning for optimism.
Advancing its diagnostic capabilities, Natera introduced a novel multi-modal artificial intelligence (AI) model designed to enhance assessments of molecular residual disease in cancer patients. This AI model synthesizes multiple data types, including circulating tumor DNA measurements and digital pathology imagery, to augment the accuracy and utility of the Signatera MRD test.
The company is also preparing to present data from its EXPAND clinical trial focused on fetal genetic screening at an upcoming Society for Maternal-Fetal Medicine conference. The EXPAND trial aims to validate a screening tool capable of identifying inherited disease-causing genetic variants in fetuses, potentially advancing prenatal diagnostics.
Moreover, recent research published in JAMA Oncology demonstrated improved survival rates among colorectal cancer patients treated with celecoxib, wherein Natera's Signatera assay contributed to monitoring minimal residual disease, underscoring its clinical relevance.